Kenderian Saad S, Porter David L, Gill Saar
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Division of Hematology/Oncology, University of Pennsylvania School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, University of Pennsylvania School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Biol Blood Marrow Transplant. 2017 Feb;23(2):235-246. doi: 10.1016/j.bbmt.2016.09.002. Epub 2016 Sep 13.
Hematopoietic cell transplantation (HCT) remains an important and potentially curative option for most hematologic malignancies. As a form of immunotherapy, allogeneic HCT (allo-HCT) offers the potential for durable remissions but is limited by transplantation- related morbidity and mortality owing to organ toxicity, infection, and graft-versus-host disease. The recent positive outcomes of chimeric antigen receptor T (CART) cell therapy in B cell malignancies may herald a paradigm shift in the management of these disorders and perhaps other hematologic malignancies as well. Clinical trials are now needed to address the relative roles of CART cells and HCT in the context of transplantation-eligible patients. In this review, we summarize the state of the art of the development of CART cell therapy for leukemia, lymphoma, and myeloma and discuss our perspective of how CART cell therapy can be applied in the context of HCT.
造血细胞移植（HCT）仍然是大多数血液系统恶性肿瘤重要且可能治愈的选择。作为一种免疫治疗形式，异基因造血细胞移植（allo-HCT）有实现持久缓解的潜力，但因器官毒性、感染和移植物抗宿主病导致的移植相关发病率和死亡率限制了其应用。嵌合抗原受体T（CART）细胞疗法近期在B细胞恶性肿瘤治疗中取得的积极成果，可能预示着这些疾病以及其他血液系统恶性肿瘤治疗模式的转变。目前需要开展临床试验，以明确在符合移植条件的患者中CART细胞和造血细胞移植各自的相对作用。在这篇综述中，我们总结了CART细胞疗法在白血病、淋巴瘤和骨髓瘤治疗方面的最新进展，并探讨我们对CART细胞疗法如何在造血细胞移植中应用的观点。
